This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • Randomized, double-blind, phase 3 study of TAS-102...
Clinical trial

Randomized, double-blind, phase 3 study of TAS-102 plus best supportive care (bsc) versus placebo plus bsc in patients with metastatic colorectal cancer refractory to standard chemotherapies

Read time: 1 mins
Last updated:25th Jun 2012
To compare the following endpoints for the TAS-102 (experimental) arm with the placebo (control) arm in patients with refractory metastatic colorectal cancer: Overall survival (OS) Progression-free survival (PFS) Safety and tolerability
Category Value
Study start date 2012-06-25

View full details